"3"^^ . . . "RIV/00216208:11110/14:10288389!RIV15-MSM-11110___" . "L\u00E9\u010Dba arteri\u00E1ln\u00ED hypertenze u pacienta s metabolick\u00FDm syndromem" . "RIV/00216208:11110/14:10288389" . "1"^^ . "Metabolick\u00FD syndrom je definov\u00E1n jako kombinace obezity, arteri\u00E1ln\u00ED hypertenze, dyslipidemie, porucha gluk\u00F3zov\u00E9ho metabolizmu a dal\u0161\u00EDch odchylek, jejich\u017E spole\u010Dn\u00E1 p\u0159\u00EDtomnost v\u00FDrazn\u011B zvy\u0161uje kardiovaskul\u00E1rn\u00ED riziko. L\u00E9\u010Dba arteri\u00E1ln\u00ED poruchy hypertenze u pacienta s metabolick\u00FDm syndromem je proto sou\u010D\u00E1st\u00ED komplexn\u00EDch re\u017Eimov\u00FDch a l\u00E9\u010Debn\u00FDch opat\u0159en\u00ED sm\u011B\u0159uj\u00EDc\u00EDch ke sn\u00ED\u017Een\u00ED celkov\u00E9ho kardiovaskul\u00E1rn\u00EDho rizika. Z re\u017Eimov\u00FDch opat\u0159en\u00ED je nezbytn\u00E9 zv\u00FD\u0161en\u00ED fyzick\u00E9 aktivity, reduk\u010Dn\u00ED dieta s omezen\u00EDm soli a se snahou o sn\u00ED\u017Een\u00ED hmotnosti a zanech\u00E1n\u00ED kou\u0159en\u00ED. Z antihypertenziv preferujeme ACE-inhibitory \u010Di blok\u00E1tory AT1-receptoru v kombinaci s kalciov\u00FDmi blok\u00E1tory, event. v trojkombinaci s diuretiky \u010Di jin\u00FDmi antihypertenzivy. Samoz\u0159ejmost\u00ED by m\u011Bla b\u00FDt i intenzivn\u00ED l\u00E9\u010Dba diabetu, dyslipidemie a intervence dal\u0161\u00EDch kardiovaskul\u00E1rn\u00EDch rizikov\u00FDch faktor\u016F."@cs . "Medic\u00EDna pro praxi" . . "L\u00E9\u010Dba arteri\u00E1ln\u00ED hypertenze u pacienta s metabolick\u00FDm syndromem"@cs . "Treatment of arterial hypertension in patient with metabolic syndrome"@en . "L\u00E9\u010Dba arteri\u00E1ln\u00ED hypertenze u pacienta s metabolick\u00FDm syndromem" . "L\u00E9\u010Dba arteri\u00E1ln\u00ED hypertenze u pacienta s metabolick\u00FDm syndromem"@cs . . "Haluz\u00EDk, Martin" . . . "[344D309EA970]" . . "Treatment of arterial hypertension in patient with metabolic syndrome"@en . "25863" . . "CZ - \u010Cesk\u00E1 republika" . . "11110" . . "11" . . "1214-8687" . . "V" . . . "http://www.medicinapropraxi.cz/pdfs/med/2014/04/02.pdf" . . . "1"^^ . "AT1-receptor blockers; ACE inhibitors; insulin resistance; metabolic syndrome; Arterial hypertension"@en . "4" . "Metabolic syndrome is defined as a combination of obesity, arterial hypertension, dyslipidemia, impaired glucose metabolism and other pathologies that in combination markedly increase cardiovascular risk. The treatment of arterial hypertension in patient with metabolic syndrome is an important part of complex lifestyle and therapeutic measures aiming at lowering total cardiovascular risk. Increased physical activity, hypocaloric diet with sodium restriction and smoking cessation represent an integral part of lifystele measures. Pharmacological treatment of choice are ACE-inhibitors or AT1-receptor blockers in combination with calcium channel blockers combined with other antihypertensive agents such as diuretics, beta-blockers and others, if necessary. Intensive treatment of diabetes, dyslipidemia and the intervention of other cardiovascular risk factors is another important part of complex therapeutic approach."@en . "Metabolick\u00FD syndrom je definov\u00E1n jako kombinace obezity, arteri\u00E1ln\u00ED hypertenze, dyslipidemie, porucha gluk\u00F3zov\u00E9ho metabolizmu a dal\u0161\u00EDch odchylek, jejich\u017E spole\u010Dn\u00E1 p\u0159\u00EDtomnost v\u00FDrazn\u011B zvy\u0161uje kardiovaskul\u00E1rn\u00ED riziko. L\u00E9\u010Dba arteri\u00E1ln\u00ED poruchy hypertenze u pacienta s metabolick\u00FDm syndromem je proto sou\u010D\u00E1st\u00ED komplexn\u00EDch re\u017Eimov\u00FDch a l\u00E9\u010Debn\u00FDch opat\u0159en\u00ED sm\u011B\u0159uj\u00EDc\u00EDch ke sn\u00ED\u017Een\u00ED celkov\u00E9ho kardiovaskul\u00E1rn\u00EDho rizika. Z re\u017Eimov\u00FDch opat\u0159en\u00ED je nezbytn\u00E9 zv\u00FD\u0161en\u00ED fyzick\u00E9 aktivity, reduk\u010Dn\u00ED dieta s omezen\u00EDm soli a se snahou o sn\u00ED\u017Een\u00ED hmotnosti a zanech\u00E1n\u00ED kou\u0159en\u00ED. Z antihypertenziv preferujeme ACE-inhibitory \u010Di blok\u00E1tory AT1-receptoru v kombinaci s kalciov\u00FDmi blok\u00E1tory, event. v trojkombinaci s diuretiky \u010Di jin\u00FDmi antihypertenzivy. Samoz\u0159ejmost\u00ED by m\u011Bla b\u00FDt i intenzivn\u00ED l\u00E9\u010Dba diabetu, dyslipidemie a intervence dal\u0161\u00EDch kardiovaskul\u00E1rn\u00EDch rizikov\u00FDch faktor\u016F." .